Carolinas HealthCare System
In this Section

James Hall

James B. Hall, MD
Director of Gynecologic Oncology
Department of Obstetrics and Gynecology
Clinical Professor, Department of Obstetrics and Gynecology, UNC Chapel Hill

Prior Positions and Experience

1990-present Director of Gynecologic Oncology, Dept. of OB/GYN, Carolinas Medical Center/Levine Cancer Institute
1988-1994 Private Practice, Women’s Specialty Center, Nalle Clinic (Charlotte)
1988-1990 Acting Chairman and Director, Department of Obstetrics and Gynecology, CMC
1986-1988 Associate Professor, Dept. of Obstetrics and Gynecology, University of North Carolina at Chapel Hill
1980-1986 Assistant Professor, Dept. of Obstetrics and Gynecology, UNC-Chapel Hill
1980-1988 Director, Gynecologic Oncology, Department of Obstetrics and Gynecology, Charlotte Memorial Hospital
1979-1980 Instructor in Gynecologic Oncology, Harvard Medical School (Boston)
1978-1980 Fellow in Gynecologic Oncology, Massachusetts General Hospital (Boston)
1975-1978 Resident in Obstetrics & Gynecology, Miami Valley Hospital (Dayton, Ohio)

Education

Rotating Intern in Obstetrics & Gynecology: 1974-1975, Miami Valley Hospital (Dayton, Ohio)
MD: 1974, Medical University of South Carolina
BA: 1969, Taylor University (Upland, Ind.)

Research Interests

Dr. Hall’s main research interest is in the area of clinical research relative to ovarian, cervical and endometrial cancers. He is involved as a co-investigator in studies for the National Cancer Institute through their research relationship with the Gynecologic Oncology Group. This relationship has enabled Carolinas HealthCare System to be involved in a number of seminal studies which are the basis for management of many of the gynecologic cancers. He is actively involved in clinical research with the major pharmaceuticals; this relationship has afforded the Gynecologic Oncology Division of the Department of Obstetrics and Gynecology the opportunity to offer their patients cutting edge technology and chemotherapy even prior to release to the general public. He has also been involved as the primary investigator as the initiator of a number of other studies.

In addition to clinical research interests, Dr. Hall is involved with his colleagues in work at the Sonia Wyatt Memorial Laboratory as part of the Cannon Research Institute, looking at the expression of HOX genes in ovarian cancer. Additionally, they are attempting to define the molecular pathways which are common in tumorogenesis by looking at gene expression profiles in ovarian tissue. This work involves both the evaluation of normal/benign ovaries against the comparator of malignant ovarian tissue.

Recent Publications

Vergote I, Finkler Nj, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG.  Randomized Phase III Study of Canfosfamide in Combination With Pegylated Doxorubicin Compared With Peylated Doxorubicin ALond in Platinum-Resistant Ovarian Cancer.  Int J Gynecol Cancer 2010; 20(5): 772-780. [PMID: 20973267]

Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007; 104: 727-731. [PMID: 17126894]

Mougeot JL, Bahrani-Mostafavi Z, Vachris JC, McKinney KQ, Gurlov S, Zhang J, Naumann RW, Higgins RV, Hall JB. Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesis. J Mol Biol 2006; 358: 310-329. [PMID: 16503337]

Hall JB. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol 2006; 195: 574-576 (discussion). [PMID: 16890558]

Hall JB. Rate of pathology from atypical glandular cell pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol 2006; 108: 1034. [PMID: 17012481]

Higgins RV, Naumann WR, Hall JB, Haake M. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol 2003; 89: 499-503. [PMID: 12798718]

About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy Policy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.